Literature DB >> 11155189

Fundamental concepts in the pathobiology of heparin-induced thrombocytopenia.

J L Januzzi1, I K Jang.   

Abstract

Heparin-induced thrombocytopenia (HIT) is among the most common causes of drug-related immune-mediated thrombocytopenia. It is a unique syndrome, in that despite the fact that thrombocyto-penia is the major laboratory manifestation of HIT, its major complication is a highly morbid (and commonly fatal) thrombotic diathesis, known as the HIT with thrombosis syndrome (HITTS). The pathogenesis of HIT and HITTS has been recently elucidated, and involves an immune response against epitopes within circulating heparin-platelet factor-4 (PF4) complexes. This leads to cross-linking and activation of platelets, increasing the risk for thromboses. Furthermore, significant immunological cross-reactivity occurs between endothelial-cell bound PF4 and the HIT antibody, which may lead to endothelial damage, activation, and hyperplasia. This complex process leads to a hypercoagulable state, which may lead to overt thromboses.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11155189     DOI: 10.1023/a:1027320917297

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  33 in total

1.  Antibodies from patients with heparin-induced thrombocytopenia/thrombosis recognize different epitopes on heparin: platelet factor 4.

Authors:  J S Suh; R H Aster; G P Visentin
Journal:  Blood       Date:  1998-02-01       Impact factor: 22.113

2.  Importance of the FcgammaRIIa-Arg/His-131 polymorphism in heparin-induced thrombocytopenia diagnosis.

Authors:  C Bachelot-Loza; R Saffroy; D Lasne; G Chatellier; M Aiach; F Rendu
Journal:  Thromb Haemost       Date:  1998-03       Impact factor: 5.249

3.  Heparin-induced thrombocytopenia: new insights into the impact of the FcgammaRIIa-R-H131 polymorphism.

Authors:  L E Carlsson; S Santoso; G Baurichter; H Kroll; S Papenberg; P Eichler; N A Westerdaal; V Kiefel; J G van de Winkel; A Greinacher
Journal:  Blood       Date:  1998-09-01       Impact factor: 22.113

4.  Purification and binding properties of human platelet factor four.

Authors:  R I Handin; H J Cohen
Journal:  J Biol Chem       Date:  1976-07-25       Impact factor: 5.157

5.  Drug-induced thrombocytopenia is associated with increased binding of IgG to platelets both in vivo and in vitro.

Authors:  J G Kelton; D Meltzer; J Moore; A R Giles; W E Wilson; R Barr; J Hirsh; P B Neame; P J Powers; I Walker; F Bianchi; C J Carter
Journal:  Blood       Date:  1981-09       Impact factor: 22.113

6.  Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia.

Authors:  L Ziporen; Z Q Li; K S Park; P Sabnekar; W Y Liu; G Arepally; Y Shoenfeld; T Kieber-Emmons; D B Cines; M Poncz
Journal:  Blood       Date:  1998-11-01       Impact factor: 22.113

7.  Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia.

Authors:  T E Warkentin; C P Hayward; L K Boshkov; A V Santos; J A Sheppard; A P Bode; J G Kelton
Journal:  Blood       Date:  1994-12-01       Impact factor: 22.113

8.  Prevalence and significance of haematological abnormalities in patients with systemic lupus erythematosus.

Authors:  J C Nossent; A J Swaak
Journal:  Q J Med       Date:  1991-07

9.  Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells.

Authors:  G P Visentin; S E Ford; J P Scott; R H Aster
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

10.  Gold-induced thrombocytopenia. A clinical and immunogenetic study of twenty-three patients.

Authors:  J S Coblyn; M Weinblatt; D Holdsworth; D Glass
Journal:  Ann Intern Med       Date:  1981-08       Impact factor: 25.391

View more
  3 in total

Review 1.  Limitations of conventional anticoagulant therapy and the promises of non-heparin based conformational activators of antithrombin.

Authors:  Qudsia Rashid; Poonam Singh; Mohammad Abid; Mohamad Aman Jairajpuri
Journal:  J Thromb Thrombolysis       Date:  2012-08       Impact factor: 2.300

Review 2.  Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients.

Authors:  Daniela R Junqueira; Liliane M Zorzela; Edson Perini
Journal:  Cochrane Database Syst Rev       Date:  2017-04-21

3.  Elucidating the specificity of non-heparin-based conformational activators of antithrombin for factor Xa inhibition.

Authors:  Qudsia Rashid; Mohammad Abid; Mohamad Aman Jairajpuri
Journal:  J Nat Sci Biol Med       Date:  2014-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.